Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Pfizer Changes Its Mind, Will Sell Down Stake in GSK's Haleon Unit

Stock Markets Jun 01, 2022 08:44AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.

By Geoffrey Smith 

Investing.com -- Pfizer (NYSE:PFE) will sell down its stake in Haleon, the consumer healthcare unit of GSK (LON:GSK), after its listing in London planned for later this month, GSK said on Wednesday.

That indicates a change of heart on the part of the U.S. pharma giant, which owns 32% of the group behind such brands as Voltaren joint pain cream and Sensodyne toothpaste. GSK had said earlier this year when it announced the spin-off plan, that Pfizer would hold on to its shares and have representation on its board.

The news creates an unwelcome stock hangover effect for GSK as it prepares for a deal that it hopes will lighten its balance sheet and sharpen its focus on cancer and immunology drugs. The U.K. company said, however, that Pfizer had agreed to reduce its stake in “a disciplined manner” under a marketing agreement with GSK, after a lockup period of “several months”.

Under the terms of the demerger plan, GSK will keep a stake of around 6% in Haleon for now but it intends to monetize that in due course, to fund its future investments in developing or buying new drugs. Another 7.5% stake will be held by mechanisms to support its pension plan, while GSK shareholders will receive shares accounting for just under 55% of the company.

Under pressure from activist investor Elliott Management, GSK chief executive Emma Walmsley has decided to shed the cash-generative but staid business to pursue the higher valuations typically enjoyed by companies that specialize in developing new drugs. Walmsley rejected an offer of 50 billion pounds ($63 billion) from Unilever (NYSE:UL) earlier this year as too low, stressing that it expects organic sales growth of between 4% and 6% in the medium term.

GSK's new focus was evident earlier this week in its acquisition of U.S.-based vaccine specialist Affinivax for up to $3.3 billion. It also agreed to pay $1.9 billion for Sierra Oncology (NASDAQ:SRRA) in April.

GSK stock was up 0.1% by 8:40 AM ET (1240 GMT) in London trading, while Pfizer stock was up 0.2%.

 
Pfizer Changes Its Mind, Will Sell Down Stake in GSK's Haleon Unit
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email